<?xml version="1.0" encoding="UTF-8"?>
<p>Remdesivir (RDV, GS-5734) is a broad-spectrum antiviral drug developed by the biopharmaceutical company Gilead Sciences that is currently being tested as a potential treatment for COVID-19 in international, multi-site clinical trials (
 <xref rid="B33" ref-type="bibr">33</xref>). The development of RDV was originally started by veterinary and animal professionals and focused on treating cats with feline infectious peritonitis (FIP) but this fact has been largely ignored by the press and almost forgotten by the scientific community. This is not an uncommon problem in science especially when disciplines remain focused on their own fields and do not communicate more widely. There are numerous examples of the benefits of taking a “One Health” approach in developing new therapeutics and novel medicines.
</p>
